Contact Us
Drug Search Results
More Filters [+]

Quisinostat

Alternative Names: quisinostat, jnj-26481585
Latest Update: 2024-05-03
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: HDAC Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Quisinostat

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: T-Cell Cutaneous Lymphoma|Ovarian Cancer

Phase 1: Lymphoma|Preleukemia|Myelodysplastic Syndrome|Ovarian Cancer|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
ONC-14-OvaII-1-QUI-2

P2

Completed

Ovarian Cancer

2016-12-01

51%
2011-001076-18

P2

Completed

T-Cell Cutaneous Lymphoma

2016-07-22

ONC-13-NSCLC/OVA-7-QUI-1B

P1

Completed

Ovarian Cancer|Non-Small-Cell Lung Cancer

2015-12-01

CR018640

P2

Completed

T-Cell Cutaneous Lymphoma

2014-11-01

Recent News Events

Date

Type

Title

05/03/2024

PubMed

 Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.

05/01/2024

PubMed

 New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma.

04/26/2024

PubMed

 Central Nervous System Distributional Kinetics of Selected Histone Deacetylase Inhibitors.

10/02/2020

News Article

 Cutaneous T-cell Lymphoma Market Insights, Epidemiology and Forecast, 2017-2019 & 2020-2030 - ResearchAndMarkets.com

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions